Skip to content

A randomized controlled clinical trial of polyethylene glycol losartan in the treatment of nonalcoholic steatohepatitis (NASH)

A randomized controlled clinical trial of polyethylene glycol losartan in the treatment of nonalcoholic steatohepatitis (NASH)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044996
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-04-15
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease

Interventions

control group:Glutathione
experimental group:Glutathione+polyethylene glycol losartan

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years; 2. In accordance with NASH diagnostic criteria (guidelines for prevention and treatment of nonalcoholic fatty liver disease, 2018).

Exclusion criteria

Exclusion criteria: 1. Patients with uncontrolled type 2 diabetes defined as HbA1c >= 9.5% during the screening period; (retested during the screening period for subjects with HbA1c>= 9.5%)and basal insulin dose adjustment >10% within 60 days before enrollment, and need to use glucagon-like peptide analogs or complex oral anti-diabetic (OAD) regimens (3 or more OADs) within 6 months before screening, and have a history of severe hypoglycemia in the past year (symptomatic hypoglycemia that requires external assistance to restore normal nervous system state); 3. Alcoholic, drug, viral, autoimmune, hereditary hepatitis; 4. Pregnant and lactating women; 5. With previous history of pancreatitis; 6. With pancreatitis warning / thyroid cancer; 7. Patients with hematopoietic system diseases; 8. Patients with liver cancer; 9. Incomplete data collection; 10. Without informed consent.

Design outcomes

Primary

MeasureTime frame
Blood fat;Fasting blood glucose;HbA1c;Serum insulin;HOMA-IR;Cytokeratin CK-18 (M30 and M65);Transabdominal ultrasound;Fat content determination;Liver elasticity value;

Secondary

MeasureTime frame
Weight;Waistline;BMI;Heart function;Liver function;Kidney function;Routine blood test;

Countries

China

Contacts

Public ContactZhang Yu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

whxhzy@163.com+86 13971292838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026